The PACAP receptor: a novel target for migraine treatment

Henrik W Schytz; Jes Olesen; Messoud Ashina

doi:10.1016/j.nurt.2010.02.003

The PACAP receptor: a novel target for migraine treatment

Henrik W Schytz, Jes Olesen, Messoud Ashina

53 Citationer (Scopus)

Abstract

The origin of migraine pain has not yet been clarified, but accumulating data point to neuropeptides present in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is present in sensory trigeminal neurons and may modulate nociception at different levels of the nervous system. Human experimental studies have shown that PACAP-38 infusion induces marked dilatation of extracerebral vessels and delayed migraine-like attacks in migraine patients. PACAP selectively activates the PAC(1) receptor, which suggests a possible signaling pathway implicated in migraine pain. This review summarizes the current evidence supporting the involvement of PACAP in migraine pathophysiology and the PAC(1) receptor as a possible novel target for migraine treatment.

Originalsprog	Engelsk
Tidsskrift	Neurotherapeutics
Vol/bind	7
Udgave nummer	2
Sider (fra-til)	191-6
Antal sider	6
ISSN	1933-7213
DOI	https://doi.org/10.1016/j.nurt.2010.02.003
Status	Udgivet - 1 apr. 2010

Adgang til dokumentet

10.1016/j.nurt.2010.02.003

Citationsformater

@article{0497d125f8834c15a8cb53b2be8f11e6,

title = "The PACAP receptor: a novel target for migraine treatment",

abstract = "The origin of migraine pain has not yet been clarified, but accumulating data point to neuropeptides present in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is present in sensory trigeminal neurons and may modulate nociception at different levels of the nervous system. Human experimental studies have shown that PACAP-38 infusion induces marked dilatation of extracerebral vessels and delayed migraine-like attacks in migraine patients. PACAP selectively activates the PAC(1) receptor, which suggests a possible signaling pathway implicated in migraine pain. This review summarizes the current evidence supporting the involvement of PACAP in migraine pathophysiology and the PAC(1) receptor as a possible novel target for migraine treatment.",

author = "Schytz, {Henrik W} and Jes Olesen and Messoud Ashina",

year = "2010",

month = apr,

day = "1",

doi = "10.1016/j.nurt.2010.02.003",

language = "English",

volume = "7",

pages = "191--6",

journal = "Neurotherapeutics",

issn = "1933-7213",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - The PACAP receptor: a novel target for migraine treatment

AU - Schytz, Henrik W

AU - Olesen, Jes

AU - Ashina, Messoud

PY - 2010/4/1

Y1 - 2010/4/1

N2 - The origin of migraine pain has not yet been clarified, but accumulating data point to neuropeptides present in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is present in sensory trigeminal neurons and may modulate nociception at different levels of the nervous system. Human experimental studies have shown that PACAP-38 infusion induces marked dilatation of extracerebral vessels and delayed migraine-like attacks in migraine patients. PACAP selectively activates the PAC(1) receptor, which suggests a possible signaling pathway implicated in migraine pain. This review summarizes the current evidence supporting the involvement of PACAP in migraine pathophysiology and the PAC(1) receptor as a possible novel target for migraine treatment.

AB - The origin of migraine pain has not yet been clarified, but accumulating data point to neuropeptides present in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is present in sensory trigeminal neurons and may modulate nociception at different levels of the nervous system. Human experimental studies have shown that PACAP-38 infusion induces marked dilatation of extracerebral vessels and delayed migraine-like attacks in migraine patients. PACAP selectively activates the PAC(1) receptor, which suggests a possible signaling pathway implicated in migraine pain. This review summarizes the current evidence supporting the involvement of PACAP in migraine pathophysiology and the PAC(1) receptor as a possible novel target for migraine treatment.

U2 - 10.1016/j.nurt.2010.02.003

DO - 10.1016/j.nurt.2010.02.003

M3 - Journal article

SN - 1933-7213

VL - 7

SP - 191

EP - 196

JO - Neurotherapeutics

JF - Neurotherapeutics

IS - 2

ER -

The PACAP receptor: a novel target for migraine treatment

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater